The mechanism of action and anti-tumor principle of brigatinib/brigatinib (Embry)

Brigatinib/Brigatinib (Brigatinib) is an oral targeted drug used to treat ALK-positive non-small cell lung cancer. Its core advantages are stronger target binding ability and wider coverage of multiple drug-resistant mutations. Understanding the mechanism of action of brigatinib can help patients have a clearer understanding of why the drug is effective and why it can play a valuable role in multi-line treatment. It can also improve confidence and compliance during treatment. In overseas guidelines and professional pharmacological materials, brigatinib is often classified as a second-generation ALK inhibitor, but its molecular design is closer to the "broad-spectrum ALK inhibition framework" and therefore performs better in controlling drug resistance-related mutations.

The main target of brigatinib is ALK (anaplastic lymphoma kinase) fusion protein. For some lung cancer patients, abnormal fusion of the ALK gene will drive cancer cells to continue to grow and gain invasiveness, and brigatinib can block its downstream signaling pathways by binding to the ALK kinase domain. Especially in terms of cell proliferation, metabolic regulation, cell migration and anti-apoptotic signaling, the drug can precisely intervene, causing tumor cells to gradually lose their ability to "continue to grow" and at the same time promote abnormal cells to enter the natural apoptosis process. This method of "directional blocking" is an important basis for modern precision medical treatment.

Compared with first-generation ALK inhibitors Brigatinib's structure is more suitable for binding to the ALK kinase pocket that has been altered by mutations, and therefore can inhibit multiple key mutations that lead to resistance. Overseas research materials often mention that after receiving treatment, cancer cells will try to evade immunity and drugs through changes in genetic sites. Brigatinib's ability to "adapt multiple mutant conformations" can intercept the drug resistance development path of cancer cells and maintain the continuity of treatment. From the perspective of practical application, this mechanism may be clinically effective as it may still be effective for patients who have failed previous treatments, providing them with new treatment options.

Another major mechanism feature of brigatinib is the joint blockade of transmembrane and intracellular signaling pathways. For example ALK activation will activate key pathways such as PI3K-AKT, JAK-STAT and MAPK, which are all related to the enhanced growth ability of cancer cells and their insensitivity to external pressure. By inhibiting the activity of these pathways, brigatinib gradually returns the tumor microenvironment to a normal metabolic state, making it more difficult for cancer cells to survive. This "multi-pathway regulation" mode of action gives it strong pharmacological advantages in controlling tumor spread and delaying disease progression.

The molecular structure of brigatinib also has"Crossing the blood-brain barrier" property. This means that the drug can enter the central nervous system and provide certain therapeutic value for common cases of brain metastasis. Among patients with ALK-positive lung cancer, brain metastases are more common. This feature of brigatinib is generally considered to be its key therapeutic highlight overseas, helping to achieve systemic disease management, allowing the drug to not only control lung lesions, but also take into account potential lesions in the nervous system.

At the cellular level, brigatinib can also reduce the migration speed of cancer cells and inhibit the formation of new micrometastases. Targeted After blocking the ALK signaling pathway, the adhesion and movement abilities of tumor cells will be significantly reduced, thereby reducing the risk of spread. Although this process is invisible to the naked eye, it is important in delaying the progression of the disease.

Reference materials:https://www.alunbrig.com/